Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI
Go back to Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI| TETRAPH PHARMA (NASDAQ: TTPH) | Delayed: 2.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.20 | 52 Week High | $12.45 | |||
| Open | $17.31 | 52 Week Low | $3.11 | |||
| Day High | $2.20 | P/E | N/A | |||
| Day Low | $2.20 | EPS | $-2.70 | |||
| Volume | 105,485 | |||||
